On this episode of the Health & Veritas podcast, Howard Forman and Harlan Krumholz react to President Joe Biden’s declaration that the pandemic is over. Then they’re joined by Jonathan Rothberg, a Yale-trained scientist who has created new methods for sequencing DNA and founded a series of successful biotech companies.
Negotiation expert Prof. Barry Nalebuff argues that setting the price cap either too high or too low could lead to failure and defeat the effort to make Putin pay for his aggression.
Stakeholder capitalism is not new, argues Prof. Jeffrey Sonnenfeld. Despite political backlash against “woke” CEOS, today’s leaders need to account for the broad strategic environment in which their companies operate.
On this episode of the Health & Veritas podcast, Howard Forman and Harlan Krumholz discuss the confusion over COVID therapeutics, even among professionals. Then they’re joined by Dr. Jeremy Faust, a researcher, emergency physician, and public voice on COVID and other issues—as well as an active choral conductor. They discuss his unusual path, the state of the pandemic, and the importance of understanding “excess mortality.”
The scramble for subscribers has been a boon for consumers. But changes are coming as investors demand returns. We talked to analyst Michael Nathanson ’90 about what will be left when the dust settles.
A new study co-authored by Yale SOM’s Gal Zauberman finds that apps that track calories with a photo are appealing, but manually logging your meals is actually more effective. The results offer a cautionary tale about giving consumers what they think they want, he says.
On this episode of the Health & Veritas podcast, Harlan Krumholz outlines his new study tracking excess mortality over the course of the pandemic in the highly vaccinated state of Massachusetts; Howard Forman discusses how the Inflation Reduction Act will tackle drug prices. They’re joined by Dr. Esther Choo to talk about life as a doctor on social media and the crisis facing emergency departments.
We asked Prof. Fiona Scott Morton, an expert on competition in the healthcare industry, whether the new legislation will make a difference—and what it will take to get drug prices under control.
Yale SOM’s Jeffrey Sonnenfeld and Steven Tian, who have been tracking companies’ disengagement from Russia, write that Asian airlines, European aviation giants, and sanctions evaders are gaming the system and gaining an advantage over their American competitors.
We asked SOM’s Paul Goldsmith-Pinkham, whose current work focuses on assessing the costs and benefits of debtor protection policies and understanding the role that consumer debt plays in the macroeconomy, to put President Biden’s decision to forgive student debt in context.